Psychedelic.Healthcare
Evidence-based guidance for psychedelic-assisted care
Clear, clinically reviewed information on psychedelic therapy, safety, legal access, costs, and care options in Canada, the United States, and beyond.
For Patients And Families
Make safer, better-informed treatment decisions.
Learn what different therapies involve, who may or may not be a candidate, how access works, what treatment may cost, and what to ask before choosing a provider.
For Clinicians And Referrers
Review evidence, access rules, and referral considerations.
Find concise clinical context on investigational therapies, contraindications, scope boundaries, training, and patient education resources.
Interactive Tool
Compare psychedelic therapy training pathways.
Clinicians can compare starting points by professional role, province, experience, and training goal before reviewing programs or asking their regulator about scope.
Training pathway comparator
Built for Canadian clinicians evaluating foundations, integration, ketamine-assisted therapy, SAP-informed practice, or prescriber oversight.
Open the training toolTreatment Pathways
Compare therapies without hype.
Our treatment guides explain evidence, risks, legal status, access, costs, and provider evaluation before care navigation.
Ketamine Therapy
Clinical guidance on off-label ketamine treatment, ketamine-assisted psychotherapy, IV protocols, safety, and cost.
Psilocybin-Assisted Therapy
Evidence, access pathways, Health Canada SAP considerations, clinical trials, and jurisdiction-specific legal context.
MDMA-Assisted Therapy
Investigational treatment guidance for PTSD, access pathways, safety considerations, and regulatory status.
Esketamine / Spravato
Plain-language information on approved indications, REMS-style supervision, insurance, and provider evaluation.
Access By Jurisdiction
Guidance for Canada and the United States.
Psychedelic laws and clinical availability differ by country, province, state, treatment type, and prescribing pathway. We separate what is approved, off-label, investigational, or not legally available in each context.
Canada
Find guidance on ketamine access, psilocybin and MDMA legal pathways, cost basics, safety context, and how to evaluate care options.
United States
Find guidance on ketamine access, psilocybin and MDMA legal pathways, cost basics, safety context, and how to evaluate care options.
Cost And Insurance
Access decisions often depend on coverage and out-of-pocket cost.
Private insurance
Learn what may be covered, what is commonly excluded, and what documentation to ask a licensed provider about.
Public programs
Learn what may be covered, what is commonly excluded, and what documentation to ask a licensed provider about.
Appeals guidance
Learn what may be covered, what is commonly excluded, and what documentation to ask a licensed provider about.
Safety And Evidence
Safety is part of trust.
Evidence display
Clinical claims need credible sources. Legal claims need regulators, government sources, statutes, or professional bodies.
Crisis guidance
If someone is in immediate danger, call emergency services. In Canada or the United States, call or text 988 for suicide crisis support.
Find Care Disclosure
Provider listings are informational, labeled, and separate from editorial guidance.
Provider listings do not constitute medical advice, endorsement, or a guarantee of care quality. Paid, sponsored, or affiliate-supported listings are labeled where applicable. Editorial content is produced separately from provider listing relationships.
Editorial Trust
How this resource earns trust.
Guide Library
Browse topic areas
Explore treatment, condition, access, cost, training, population, and location guides organized by topic.
Treatments
Treatments
Review evidence, safety, access, cost, and provider questions for ketamine, psilocybin-assisted therapy, MDMA-assisted therapy, and esketamine/Spravato.
70 guides
Conditions
Conditions
Explore condition-specific guides for depression, PTSD, anxiety, chronic pain, substance use, end-of-life distress, and other clinical contexts.
18 guides
Access And Legal
Access & Legal
Psychedelic therapy access differs by country, province, state, substance, and care model. These guides separate legal access from clinical evidence.
70 guides
Cost And Insurance
Cost & Insurance
Learn how private insurance, public programs, workers' compensation, prior authorization, and appeals may affect psychedelic-assisted care access.
20 guides
Find Care
Find Care
Use practical guidance to compare providers, understand verification labels, ask better questions, and interpret location-specific care information.
19 guides
Clinician Resources
Clinician Resources
Review training pathways, scope considerations, patient education topics, and evidence summaries for clinicians and referrers.
10 guides
Populations
Populations
Explore how age, identity, culture, disability, family role, profession, and life stage can affect psychedelic-assisted therapy decisions.
10 guides